RhumbLine Advisers
CYCN icon

RhumbLine Advisers’s Cyclerion Therapeutics CYCN Stock Holding History

RhumbLine Advisers’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1
Closed -$3 – 4269
2023
Q3 		$3 Sell
1
-21
-95% -$76 ﹤0.01% 4303
2023
Q2 		$94 Buy
+22
New +$114 ﹤0.01% 4367
2021
Q2 		– Sell
-1,708
Closed -$95K – 3018
2021
Q1 		$95K Buy
1,708
+5
+0.3% +$376 ﹤0.01% 2940
2020
Q4 		$104K Buy
1,703
+232
+16% +$15.8K ﹤0.01% 2965
2020
Q3 		$179K Sell
1,471
-234
-14% -$26.8K ﹤0.01% 2720
2020
Q2 		$202K Buy
1,705
+388
+29% +$32.4K ﹤0.01% 2767
2020
Q1 		$70K Hold
1,317
– – ﹤0.01% 2834
2019
Q4 		$72K Buy
1,317
+16
+1% +$1.49K ﹤0.01% 2901
2019
Q3 		$315K Buy
1,301
+15
+1% +$3.24K ﹤0.01% 2555
2019
Q2 		$295K Buy
+1,286
New +$364K ﹤0.01% 2614

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
TCP
Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RhumbLine Advisers's CYCN Position: Q4 2023 in Review

RhumbLine Advisers sold out of Cyclerion Therapeutics (CYCN) in Q4 2023, closing a stake of 1 share — an estimated $3 sold.

RhumbLine Advisers first reported a position in CYCN in Q2 2019 and held it in 10 quarters. The position peaked at $315K in Q3 2019. 15 funds tracked by Wall St. Rank hold CYCN as of Q4 2023.

  • RhumbLine Advisers reported no remaining Cyclerion Therapeutics position as of Q4 2023 after selling out during the quarter.
  • RhumbLine Advisers sold 1 Cyclerion Therapeutics share in Q4 2023, an estimated $3.
  • RhumbLine Advisers first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 10 quarters.
  • RhumbLine Advisers's Cyclerion Therapeutics position peaked at $315K in Q3 2019.
  • 15 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2023.

Based on RhumbLine Advisers's 13F filing for Q4 2023, filed 8 Feb 2024.